Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
J Thorac Oncol., Jan;3(1):59-67 (2008)
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
J. Clin. Oncol., Apr;26(10):1732-41 (2008)
Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma.
Ann. Oncol., Sep;19(9):1650-4 (2008)
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
Ann. Oncol., Oct;19(10):1787-94 (2008)
An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease.
Clin. Cancer Res., Aug;14(16):5255-9 (2008)
Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer.
Arch. Otolaryngol. Head Neck Surg., Oct;134(10):1060-5 (2008)
Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer.
Arch. Otolaryngol. Head Neck Surg., Nov;135(11):1133-6 (2009)
Chemoreirradiation for recurrent salivary gland malignancies.
Radiother Oncol., Jun;95(3):308-11 (2010)
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
Int. J. Radiat. Oncol. Biol. Phys., Mar;61(4):1096-106 (2005)
Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer.
Cancer J., 11(2):140-6 (2005)
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Int. J. Radiat. Oncol. Biol. Phys., Feb;64(2):382-91 (2006)
Planned post-chemoradiation neck dissection: significance of radiation dose.
Laryngoscope., Jan;116(1):33-6 (2006)
Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers.
Int. J. Oncol., May;28(5):1113-9 (2006)
Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions.
Int. J. Oncol., May;28(5):1141-51 (2006)
Aspiration in chemoradiated patients with head and neck cancer.
Arch. Otolaryngol. Head Neck Surg., Dec;133(12):1289-95 (2007)
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
J. Clin. Oncol., Jul;24(21):3438-44 (2006)
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
Clin. Cancer Res., Jan;13(2 Pt 1):515-22 (2007)
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
Cancer Invest., Sep;25(6):435-44 (2007)
Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary.
Ann. Oncol., Aug;14(8):1306-11 (2003)
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
Oncologist., 8(4):350-60 (2003)